410 Rec'd PCT/PTO 0 3 FEB 2000

e =	710113	edionio of ID 2000						
FÒRM PTO-139 (REV: 12-29-99)		TTORNEY'S DOCKET NUMBER						
	ANSMITTAL LETTER TO THE UNITED STATES	30794.3003WO 1						
	DESIGNATED/ELECTED OFFICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)						
	CONCERNING A FILING UNDER 35 U.S.C. 371 097485071							
INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED 29 August 1997								
TITLE OF INVENTION MODULATORS OF DNA CYTOSINE-5 METHYLTRANSFERASE AND METHODS FOR USE THEREOF								
APPLICANT(S) FOR DO/EO/US Norbert O. Reich and James Flynn								
Applicant	herewith submits to the United States Designated/Elected Office (DO/EO/US) the follo	owing items and other information:						
ı. X								
2.	This is a SECOND or SUBSEQUENT submission of items concerning a filing under	35 U.S.C. 371.						
3.	This express request to begin national examination procedures (35 U.S.C. 371(f)) at an							
4. X	examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and A proper Demand for International Preliminary Examination was made by the 19th mo	nd PCT Articles 22 and 39(1).						
5. X								
	a. is transmitted herewith (required only if not transmitted by the International Bureau). b. has been transmitted by the International Bureau.							
	b. has been transmitted by the International Bureau.	has been transmitted by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). tion of the International Application into English (35 U.S.C. 371(c)(2)). tents to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are transmitted herewith (required only if not transmitted by the International Bureau).						
	c. X is not required, as the application was filed in the United States Receiving Office (RO/US).							
6.	A translation of the International Application into English (35 U.S.C. 371(c)(2)).							
7. X	Amendments to the claims of the International Application under PCT Article	equired only if not transmitted by the International Bureau). the International Bureau. ver, the time limit for making such amendments has NOT expired.						
	a. are transmitted herewith (required only if not transmitted by the Inter	ing Office (RO/US).). 9 (35 U.S.C. 371(c)(3)) ational Bureau). ents has NOT expired.						
	b. have been transmitted by the International Bureau.							
	c. have not been made; however, the time limit for making such amenda	ments has NOT expired.						
	d. X have not been made and will not be made.							
8.	A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).							
9. X	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).							
10.	A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).							
Items 11. to 16. below concern document(s) or information included:								
11.	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.							
12.	An assignment document for recording. A separate cover sheet in compliance	e with 37 CFR 3.28 and 3.31 is included.						
13. X	A FIRST preliminary amendment.							
	A SECOND or SUBSEQUENT preliminary amendment.							
14.	A substitute specification.							
15.	A change of power of attorney and/or address letter.							
16. X	Other items or information:							
10. [22]								
	University of California:							
	(b) Verified statement claiming small entity status	- by EpiGenX Pharmaceutical.						

430 meca pu i/p i U INTERNATIONAL APPLICATION NO. PCT/US98/12351 30794.30USWO **CALCULATIONS** PTO USE ONLY 17. X The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO · · · · · · · International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO...... \$840.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$690.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) ENTER APPROPRIATE BASIC FEE AMOUNT \$670.00 Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)). CLAIMS NUMBER FILED NUMBER EXTRA **RATE** X \$18.00 Total claims 25 5 - 20 = \$ 90.00 Independent claims 4 X \$78.00 \$ 78.00 - 3 = MULTIPLE DEPENDENT CLAIM(S) (if applicable) \$ 135.30 + \$260.00 TOTAL OF ABOVE CALCULATIONS \$838.00 Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement 419.00 must also by filed (Note 37 CFR 1.9, 1.27, 1.28). \$419.00 Processing fee of \$130.00 for furnishing the English translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(f)). TOTAL NATIONAL FEE \$419.00 Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property TOTAL FEES ENCLOSED \$419.00 Amount to be refunded: \$ charged: a. X Please charge my Deposit Account No. ______ in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0494. A duplicate copy of this sheet is enclosed. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status. SEND ALL CORRESPONDENCE TO: CANADY, Karen S. GATES & COOPER Karen S. Canady 6701 Center Drive West, Suite 1050 NAME Los Angeles, California 90045 39,927 REGISTRATION NUMBER



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Norbert O. Reich and James Flynn

Docket:

30794.30USWO

Title:

MODULATORS OF DNA CYTOSINE-5 METHYLTRANSFERASE AND METHODS FOR

USE THEREOF

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

'Express Mail' mailing label number: EL307943991US

Date of Deposit: February 3, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service 'Express Mail Post Office To Addressee' service under 37 CFR 1.10 and is addressed to the Assistant Commissioner for Patents, Washington, D.C.

BOX PCT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

Transmittal sheet, in duplicate, containing Certificate Of Mailing Under 37 CFR 1.10.

Verified statement to establish small entity status - by The Regents of the University of California.

Verified statement to establish small entity status – by EpiGenX Pharmaceutical.

A signed Combined Declaration and Power of Attorney.

Our check No. 30105185 in the amount of \$419.00 to cover the Filing Fee.

Other: Form PTO-1390 (2 pages); a Preliminary Amendment (4 pages).

Return postcard.

CLAIMS AS FILED

Number of Claims Filed	In Excess of:	Number Extra		Rate	,	Fee	
Basic Filing Fee						\$335.00	
Total Claims							
25	20	5	х	\$9.00	=	\$45.00	
Independent Claims							
4	3	1	х	\$39.00	=	\$39.00	
MULTIPLE DEPENDENT CLAIM FEE							
TOTAL FILING FEE							

Please charge any additional fees or credit overpayment to Deposit Account No. 50-0494. A duplicate of this sheet is enclosed.

GATES & COOPER

Howard Hughes Center 6701 Center Drive West, Suite 1050 Los Angeles, CA 90045 (310) 641-8797

Name: Karen S. Canady

Reg. No.: 39,927 Initials: KSC/dr